A 340B administrative dispute resolution (ADR) panel decided late last week that it will not stop proceedings in the National Association of Community Health Centers’ (NACHC) dispute-resolution petition over drug manufacturers AstraZeneca and Sanofi’s conditions on 340B pricing when covered entities use contract pharmacies. It gave the companies until March 13 to respond to NACHC’s January 2021 complaints.
The ADR panel reached its decision on Feb. 11. “Until Congress changes the law, a court of competent jurisdiction enjoins either the ADR rule or this panel’s activities, or HHS [the U.S. Health and Human Services Department] amends or replaces the ADR rule, this panel must assume it has a mandate to hear the petitions before it,” the panel said. “Accordingly, and for the reasons set forth above, the motions for a stay are denied.”
The federal government’s 340B administrative dispute resolution (ADR) panel decided late last week that it will not stop proceedings in the National Association of Community Health Centers’ (NACHC) dispute-resolution petition over drug manufacturers AstraZeneca and Sanofi’s conditions on 340B pricing when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
